PROF
Profound Medical Corp

408
Mkt Cap
$183.65M
Volume
189,646.00
52W High
$8.95
52W Low
$3.76
PE Ratio
-3.59
PROF Fundamentals
Price
$5.06
Prev Close
$5.16
Open
$5.14
50D MA
$6.97
Beta
0.94
Avg. Volume
164,031.57
EPS (Annual)
-$1.41
P/B
2.76
Rev/Employee
$99,370.37
$182.53
Loading...
Loading...
News
all
press releases
Profound Medical (TSE:PRN) Trading Down 26% - Time to Sell?
Profound Medical (TSE:PRN) Shares Down 26% - Time to Sell...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Profound Medical (NASDAQ:PROF) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Profound Medical (NASDAQ:PROF - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.28) by...
MarketBeat·15d ago
News Placeholder
Profound Medical Q4 Earnings Call Highlights
Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring revenue and $3.7 million from one-time capital equipment sales, according to...
MarketBeat·16d ago
News Placeholder
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of 0.00% and -21.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Profound Medical Q4 Earnings Assessment
read more...
Benzinga·16d ago
News Placeholder
Profound Medical $PROF Shares Purchased by First Eagle Investment Management LLC
First Eagle Investment Management LLC raised its position in Profound Medical (NASDAQ:PROF - Free Report) by 138.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm...
MarketBeat·16d ago
News Placeholder
Profound Medical's Earnings: A Preview
read more...
Benzinga·17d ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·19d ago
News Placeholder
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Xeris Biopharma (XERS) delivered earnings and revenue surprises of +84.62% and +5.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·23d ago
<
1
2
...
>

Latest PROF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.